What it's for (Indications)
- Glibenclamide, commonly known by brand names such as Pligliben, is an oral antihyperglycemic agent indicated for the management of type 2 diabetes mellitus in adult patients.
- It is prescribed as an adjunct to diet and exercise to improve glycemic control.
- This medication is typically considered when lifestyle modifications alone, including dietary changes and a regular exercise regimen, are insufficient to achieve and maintain target blood glucose levels.
- Glibenclamide works by stimulating insulin secretion, therefore it is effective only in patients who retain some pancreatic beta-cell function.
- It is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, conditions where the body either produces no insulin or cannot effectively use it.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of glibenclamide must be individualized based on the patient's glycemic response and tolerance, with the goal of achieving optimal blood glucose control with the lowest effective dose. For standard glibenclamide formulations, the typical starting dose is 2.5 mg to 5 mg orally once daily with breakfast or the first main meal. Dosage adjustments should be made gradually, usually in increments of 2.5 mg or 5 mg at weekly intervals, based on regular monitoring of fasting blood glucose and HbA1c levels. The maximum recommended daily dose generally does not exceed 20 mg. For micronized glibenclamide, lower starting doses (e.g., 1.25 mg to 2.5 mg once daily) and a lower maximum daily dose (e.g., 10 mg) may apply due to enhanced bioavailability. Doses exceeding 10 mg daily are often divided to be taken twice a day with meals to minimize gastrointestinal upset and potentially reduce the risk of hypoglycemia. Renal and hepatic impairment necessitate careful dose titration and monitoring. |
Safety & Warnings
Common Side Effects
- The most significant and frequently encountered adverse effect of glibenclamide is hypoglycemia, which can range from mild to severe and potentially life-threatening.
- Other common side effects include gastrointestinal disturbances such as nausea, epigastric fullness, heartburn, and occasional anorexia.
- Dermatological reactions, including rash, pruritus, urticaria, and photosensitivity, have been reported.
- Less common but serious adverse events include cholestatic jaundice, which necessitates immediate discontinuation of the drug, and various hematologic disorders such as leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, and aplastic anemia, all of which are rare.
- Some patients may experience weight gain as a metabolic consequence of improved glycemic control and increased insulin secretion.
- Transient visual disturbances due to changes in blood glucose levels may occur at the initiation of therapy.
Serious Warnings
- Black Box Warning: Glibenclamide, like all sulfonylurea medications, carries a serious warning regarding the potential for severe hypoglycemia. While not formally designated with an FDA 'Black Box Warning,' it is critical to emphasize that hypoglycemia can be profound, prolonged, and may require hospitalization, potentially leading to permanent neurological damage or even death. This risk is heightened in elderly patients, those with impaired renal or hepatic function, adrenal or pituitary insufficiency, malnourished individuals, and patients taking other medications that can potentiate the hypoglycemic effect of glibenclamide (e.g., NSAIDs, sulfonamides, warfarin, fibrates, alcohol). Factors such as irregular meal patterns, strenuous exercise, or excessive alcohol intake further exacerbate this risk. Patients and caregivers must be thoroughly educated on the symptoms of hypoglycemia and appropriate management strategies. Careful dose titration and vigilant monitoring of blood glucose levels are essential to mitigate this serious risk, especially during initial therapy and any dose adjustments. Due to its long half-life, a single episode of hypoglycemia may necessitate extended observation.
- Patients treated with glibenclamide are at risk of developing hypoglycemia, especially the elderly, those with impaired renal or hepatic function, adrenal or pituitary insufficiency, and those who are malnourished or concurrently using other glucose-lowering agents or drugs that potentiate glibenclamide's effect.
- Alcohol consumption can also increase the risk and severity of hypoglycemia.
- Caution is advised in patients with G6PD deficiency due to the risk of hemolytic anemia.
- There is a potential for loss of glycemic control over time, known as secondary failure, which may necessitate a change in therapeutic regimen.
- Glibenclamide should be used with extreme caution in patients with cardiovascular disease due to historical concerns regarding increased cardiovascular mortality associated with first-generation sulfonylureas, though this risk is debated for second-generation agents.
- During periods of stress, such as fever, trauma, infection, or surgery, the dosage of glibenclamide may need adjustment, or insulin therapy may be temporarily required to maintain glycemic control.
How it Works (Mechanism of Action)
Glibenclamide belongs to the sulfonylurea class of oral antihyperglycemic agents. Its primary mechanism of action involves stimulating insulin release from the pancreatic beta cells. This effect is achieved by binding to the sulfonylurea receptor 1 (SUR1) subunit of the ATP-sensitive potassium (K_ATP) channels located on the beta-cell plasma membrane. The binding of glibenclamide to SUR1 leads to the closure of these K_ATP channels, which in turn causes depolarization of the beta-cell membrane. This depolarization subsequently opens voltage-gated calcium channels, leading to an influx of extracellular calcium into the beta cell. The increase in intracellular calcium concentration triggers the exocytosis of insulin-containing granules, resulting in enhanced insulin secretion. This insulin release is glucose-dependent, although it can occur at lower glucose levels than endogenous physiological insulin secretion, increasing the risk of hypoglycemia. Glibenclamide's action is dependent on the presence of functional beta cells.